Company / Shareholders' Equity
Monte Rosa Therapeutics, Inc. Shareholders' Equity History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$222.9M
FY2024
5-year range
-$48.7M / $347.5M
FY2020-FY2024
Trend
+24.4%
vs FY2023
Sector context
#150 of 213
Health Care
What the data says
At $223M, Monte Rosa Therapeutics, Inc.'s shareholders' equity ranks #150 of 213 in the Health Care sector. Shareholders' Equity returned to growth in FY2024 after 2 years of decline, reaching $223M.
Based on SEC 10-K filings.
$223M in FY2024 with a 3-year CAGR of -13.8%.
Declined from $271M to $223M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -13.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#150 of 213 in Health CareTop 70% of 213This company $222.9M Sector average $2.5B
▼
-91.3% below sector average
Key checks
Key Insights
- 3-year CAGR of -13.8%, indicating a declining trend.
- In FY2024, shareholders' equity increased 24.4% year-over-year.
- Ranks #150 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 0.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $222.9M | +24.4% |
| FY2023 | $179.3M | -34.0% |
| FY2022 | $271.4M | -21.9% |
| FY2021 | $347.5M | +813.2% |
| FY2020 | -$48.7M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026